Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom. Show more

The Mediaworks, White City, London, W12 7FP, United Kingdom

https://www.autolus.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

383.2M

52 Wk Range

$1.10 - $2.70

Previous Close

$1.44

Open

$1.45

Volume

1,094,406

Day Range

$1.44 - $1.51

Enterprise Value

80.34M

Cash

367.4M

Avg Qtr Burn

-67.9M

Insider Ownership

5.56%

Institutional Own.

78.99%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
AUCATZYL® (obecabtagene autoleucel) (obe-cel) Details Acute lymphoblastic leukemia, Cancer, Blood cancer	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AUCATZYL/Obecabtagene Autoleucel (AUTO1) (CD19 CAR-T) Details Lupus Nephritis	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AUCATZYL/Obecabtagene Autoleucel (AUTO1) (CD19 CAR-T) Details Pediatric Relapsed Or Refractory B-Cell Acute Lymphoblastic Leukemia And B-Cell Non-Hodgkin Lymphoma	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AUTO4 Details Peripheral T cell cancer	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
obe-cel (AUTO1) (CD19) Details Lymphoma, Leukemia, Cancer, Central nervous system illness, primary central nervous system lymphomas	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AUTO1/22 (CD19 & CD22) Details Cancer, Leukemia, Pediatric Acute lymphoblastic leukemia	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AUTO6NG Details Solid tumor/s, Neuroblastoma	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Obecabtagene Autoleucel (Obe-Cel) Details Multiple Sclerosis (MS)	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AUTO8 (BMCA & CD19) Details Multiple myeloma	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
obe-cel (AUTO1) (CD19) Details Lymphoma, Non-Hodgkin lymphoma, Chronic lymphocytic leukemia, Cancer, Leukemia	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
obe-cel (AUTO1) (CD19) Details Systemic lupus erythematosus	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AUTO5 Details T-cell lymphoma	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AUTO8 (BCMA & CD19) (BCMA CD19 CAR-T) Details Relapsed Or Refractory Light-Chain (AL) Amyloidosis	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AUTO8 (BCMA & CD19) (BCMA CD19 CAR-T) Details Relapsed Or Refractory Light-Chain (AL) Amyloidosis	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AUTO3 (CD19, CD22) Details Lymphoma, Diffuse large B cell lymphoma, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.